The gene-editing technique known as CRISPR has accelerated biological and medical research in the last decade by allowing scientists to repair the DNA of human cells almost as simply as using a pair of scissors.
The biotech expects that, by keeping its focus on more advanced projects and clinical programs, it could save on average $40 million to $50 million annually for the next several years
